A framework for integrated clinical risk assessment using population sequencing data

James D. Fife BS[1], Tho Tran MEng[2], Jackson R. Bernatchez MEng[2], Keithen E. Shepard BS[2], Christopher Koch MS[3], Aniruddh P. Patel MD[4,6,7], Akl C. Fahed MD, MPH[4,6,7], Sarathbabu Krishnamurthy[5], Regeneron Genetics Center*, DiscovEHR Collaboration*, Wei Wang PhD[6], Adam H. Buchanan MS, MPH[5], David J. Carey PhD[5], Raghu Metpally PhD[5], Amit V. Khera MD, MSc[4,6,7], Matthew Lebo PhD[3,6,8], Christopher A. Cassa PhD[1,2,6]

[1]Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
[2]Massachusetts Institute of Technology, Cambridge, Massachusetts
[3]Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine, Boston, Massachusetts
[4]Center for Genomic Medicine and Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
[5]Geisinger Health System, Danville, PA
[6]Harvard Medical School, Boston, Massachusetts
[7]Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, Massachusetts
[8]Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts
*Banner authorship information available in supplement

Please address correspondence to: Christopher Cassa cassa@alum.mit.edu

Disclosures: A.V.K. has served as a scientific advisor to Sanofi, Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Verve Therapeutics, Veritas International, Color Health, Third Rock Ventures, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; and received sponsored research agreements from the Novartis Institute for Biomedical Research and IBM Research. C.C. has served as a consultant or received honoraria from gWell Health, athenahealth, and Data Sentry Solutions. C.K. is now employed by Novartis Institutes for BioMedical Research and R.M. is now employed at Sonic Healthcare USA. The remaining authors have no disclosures.

Funding: Funding support was provided by NIH grants T32HL007208 (to A.P.P. and A.C.F.), 1K08HG010155 (to A.V.K.), 1U01HG011719 (to A.V.K.), R01HG010372 (to C.A.C. and M.L.) and R21HG010391 (to C.A.C. and J.F.) from the National Human Genome Research Institute.

Acknowledgments: We are indebted to the UK Biobank and its participants who provided biological samples and data for this analysis. Work was performed under UK Biobank application #7089 and Mass General Brigham IRB protocol 2020P002093. We are also grateful for advice and assistance from Harvard Catalyst, Dr. Shamil Sunyaev, and Dr. Richard Sherwood.

Author Contributions:
Manuscript: JF, CC with support from TT, CK, AP, AF, AB, AK, ML. Data generation: JF, CK, AP, AF, SK, Regeneron Genetics Center, DiscovEHR Collaboration, AB, DC, RM, AK, ML, CC. Statistical Analysis: JF, JB, KS, WW, CC. Model design and creation: JF, JB, KS, CC. Software : JF, TT

Abstract

Clinical risk prediction for genetic variants remains challenging even in established disease genes, as many are so rare that epidemiological assessment is not possible. Using data from 200,625 individuals, we integrate individual-level, variant-level, and protein region risk factors to estimate personalized clinical risk for individuals with rare missense variants. These estimates are highly concordant with clinical outcomes in breast cancer (BC) and familial hypercholesterolemia (FH) genes, where we distinguish between those with elevated versus population-level disease risk (logrank $p<10^{-5}$, Risk Ratio=3.71 [3.53, 3.90] BC, Risk Ratio=4.71 [4.50, 4.92] FH), validated in an independent cohort (χ^2 $p=9.9\times10^{-4}$ BC, χ^2 $p=3.72\times10^{-16}$ FH). Notably in FH genes, we predict that 64% of biobank patients with laboratory-classified pathogenic variants are not at increased coronary artery disease (CAD) risk when considering all patient and variant characteristics. These patients have no significant difference in CAD risk from individuals without a monogenic variant (logrank p=0.68). Such assessments may be useful for optimizing clinical surveillance, genetic counseling, and intervention, and demonstrate the need for more nuanced approaches in population screening.

Introduction

Mapping germline variants to personalized clinical risk is a major goal in precision medicine.[1] While clinical diagnostic testing has advanced dramatically, the interpretation of monogenic variants remains challenging, and is generally done at the variant level.[2] To date, such genetic testing has largely been conducted in the presence of a phenotypic indication, where the prior probability of detecting a causal variant is considerable.[3] Subsequent population screening efforts have identified substantial incomplete penetrance or reduced expressivity in these previously identified monogenic disease variants,[4–6] and assessed how the risk attributable to

these variants can be modified by clinical and polygenic risk factors.[7–9] The UK Biobank (UKB) provides over 200,000 exomes linked with clinical data, improving our ability to analyze risk for individuals without clinical indication.[10]

In particular, there has been great interest in understanding the prevalence and penetrance of variation in clinically actionable disease genes.[11] In this study, we analyze nine genes designated as having Tier 1 evidence for population health impact by the U.S. Centers for Disease Control and Prevention, responsible for hereditary breast and ovarian cancer (HBOC), Lynch syndrome (LS), and familial hypercholesterolemia (FH). Given their established causality in clinical syndromes, many individuals have undergone diagnostic sequencing in these genes, revealing numerous pathogenic or likely pathogenic (P/LP) variants.[12] At the population level, there is a substantial burden of such pathogenic variation: in the UKB, variants classified as P/LP within these 9 genes were identified in 0.9% of participants[13] similar to the rate identified in prior studies.[14,15]

However, these rates do not capture the true scale of the diagnostic burden in precision medicine, as there are many additional variants which could confer clinical risk.[16] There are over 18-fold more non-synonymous, rare variants (allele frequency<=0.005) observed in the population in these genes than those already classified as P/LP, making such variants collectively common **(Figure 1A)**.

Figure 1



Figure 1: Scale of the diagnostic interpretation problem in precision medicine. [a] The number of individuals who carry potentially damaging variants is over 18-fold greater than the number of diagnostic laboratory confirmed pathogenic or likely pathogenic variants. In 49,738 individuals from the UKB, an aggregate 0.89% of individuals had a diagnostic laboratory confirmed pathogenic or likely pathogenic variant.[13] However, 16.63% of individuals are expected to carry at least one rare, non-synonymous variant in the nine CDC Tier 1 actionable disease genes (gnomAD v2.1.1). Variants were restricted to non-synonymous (missense or more damaging), with allele frequency of 0.5% or less in all population groups, and were filtered by a list of regions known to present challenges in next generation sequencing and calling.[17] **[b]** Among variants which have been evaluated by a diagnostic laboratory and submitted to ClinVar, 68.4% are of uncertain or conflicting interpretation within the three disorders examined. These unresolved interpretations in clinically actionable genes pose a problem for clinical management and accurate risk prediction.[2]

Despite extensive diagnostic testing, the majority of these variants have only been observed in a few cases or controls, if at all.[3] On the basis of their low frequencies, lack of observations in clinical cases, or availability of functional data, most of these variants have been classified as variants of uncertain significance (VUS).

Among over 28,000 missense variants reviewed by clinical labs in these 9 genes, 59.5% are classified as VUS and 8.9% have conflicting interpretations, accounting for 68.4% of variants which do not have clear guidance to communicate to patients (ClinVar 6/19) **(Figure 1B)**. A recent study found that fewer than 1% of these VUS were reclassified in ClinVar over a 3.5 year period, indicating that little headway is being made on this problem.[18] These conflicting or uncertain assessments limit clinicians' ability to personalize risk management recommendations and have been reported to be associated with overtreatment (e.g., unnecessary surveillance or prophylactic surgery).[19]

This diagnostic challenge is exacerbated by the fact that conventional standards to assess pathogenicity are designed to provide clinical certainty at the *variant* level, without considering patient-specific predictive information that could influence assessments. This poses two challenges in the implementation of genomic medicine:

1) For most patients who have no clinical indication for testing (say, those prospectively screened, or in biobanks), it is unlikely they will be informed about a VUS based on current practice guidelines, even if it confers high risk. Even impressively powered Mendelian studies cannot yet address this issue for rare VUS. A recent well-designed breast cancer study of over 113,000 women found that rare missense variants in *BRCA1* and *BRCA2* which have previously been classified as pathogenic confer similar risk to protein-truncating variants (odds ratios [O.R.] 16.11 and 5.68, respectively).[20] But in contrast, the authors found that rare missense variants (in aggregate), only confer a modest risk in *BRCA1* O.R. 1.11 (p=0.01), and no significant

aggregate risk in *BRCA2* O.R. 0.98 (p=0.50).[20] In this study, we are able to significantly discriminate risk for these rare VUS at the variant level, potentially expanding the breadth of risk data that can be used to improve clinical care.

2) The current focus on variant-level interpretation leaves patient-specific predictive information (*e.g.* sex, polygenic risk, family history) out of clinical risk assessments. Considering the magnitude with which these characteristics can modify monogenic disease risk in some disorders and can contribute to penetrance of disease-causing variants,[9,21] it is prudent to integrate them to distinguish between *patients* at higher and lower risk. Adjusting clinical risk assessments using these features could better inform preventive medicine and surveillance, improve genetic counseling, and even optimize therapeutic interventions.[22]

Here, we integrate patient-level risk factors to provide personalized assessments. We develop predictions in nine disease genes, using variant-level annotations (allele frequency, computational predictive tools, protein region, and functional consequence) as well as individual-level risk factors (polygenic risk, family history, and sex). We use these estimates to understand the distribution of clinical risk associated with existing diagnostic classifications (P, LP, and VUS), to classify patients as having higher or lower clinical risk, and to identify patients with known pathogenic variants who may be at lower risk. We also provide a web application to generate these personalized predictions.

Results

Integrating individual-level risk factors in clinical predictions

To personalize risk estimates, we include family history from participant survey data, previously generated and validated in the UKB.[13] As has been shown in longitudinal population studies, family history of breast cancer, bowel cancer, and heart disease are significantly predictive clinical risk factors **(Supplementary Table 1**).[13] Previous studies have demonstrated the utility of genome-wide PRS in risk stratification[23] and in assessing the variable penetrance or expressivity of monogenic variants.[24] Similarly, PRS has been shown to modify clinical risk in individuals with germline coding variants in the UKB for these disorders,[9] which we also find to be significantly predictive (**Supplementary Table 1**). Though non-additive interactions between PRS and monogenic variants have been previously identified in these phenotypes,[25,26] a previous analysis in this cohort did not find significant interactions, on the basis of limited statistical power to detect it.[9] Accordingly, these terms were not included in the model, but could be added to gene-based models fit on sufficiently powered cohorts.

Variant-level predictors of functional and evolutionary effects

We next analyzed variant-level features that would be expected to influence clinical risk, including allele frequency, functional consequence, sequence context, and computational predictions of conservation and pathogenicity. Variant annotation and quality control filtering were completed as described in the Methods. Consistent with prior studies, individuals with missense variants only confer a modest average increase in clinical risk in some genes **(Supplementary Figure 1, Supplementary Table 1)**.[20] However in other genes, missense variants are significantly associated with excess clinical risk (*LDLR* missense hazard ratio (HR)=1.32 [1.07, 1.63], p=0.0097, loss-of-function (LOF) HR=6.61 [2.97, 14.72], $p=3.78 \times 10^{-6}$).

As expected, we find significant hazards associated with many other variant-level features, including computational predictions of variant pathogenicity and conservation, including high GERP (Genomic Evolution Rate Profiling)[27,28] (*LDLR* HR=1.50 [1.12, 2.02], p=0.0069) or CADD (Combined Annotation Dependent Depletion) scores,[29] $p=7.93 \times 10^{-6}$), and low allele frequency (HR=1.4 [1.08, 1.82], p=0.012). These variant-level predictive features conferred varying levels of risk by gene and disorder **(Supplementary Table 1)**. Accordingly, feature selection was carried out individually per gene model (see Methods).

Defining protein regions with differential clinical risk

While it is expected that some missense variants will result in substantially altered protein function,[30] many others will confer limited clinical risk. Variants that are within protein domains[31,32] and in proximity in the folded protein[33] to pathogenic variants are expected to be under increased negative selection. Accordingly, proximity to such variation may also confer increased clinical risk,[34] and is considered moderate evidence in support of pathogenicity in clinical assessment.[2] Conversely, there may also be “cold spots,” where most variation is expected to be neutral[35] or other regions where mutations may confer protective effects.[36] Given the broad spectrum of potential impacts of missense variants and the utility of proximal variation, we sought to define regional risk to quantitatively discriminate between missense variants with lower or higher risk.

To define regions of differential clinical risk, we make use of the abundant clinical diagnostic data in these genes from ClinVar, curated independently from the UKB. We filter to known pathogenic single nucleotide variants which would be expected to impact a specific region rather than have a downstream effect (*e.g.* non-terminating, non-splice, non-frameshift variants,

see Methods). We then use one-dimensional optimization to partition the protein into regions with differential rates of pathogenic variation. The number of protein regions is specified based on the coding sequence length (*e.g.* 13 regions for *APOB*: 13,689bp, 5 regions for *BRCA1*: 5,589bp) with a minimum of 5 regions (**Figure 2A**). Regions without adequate sequence coverage are treated as missing.

Figure 2
[a]



[b]



Figure 2: Defining regions within each protein with differing clinical risk. We identify regions in each gene that are associated with higher- and lower-risk for breast cancer (BC) and coronary artery disease (CAD) using previously identified pathogenic variants (ClinVar) without the use of UKB patient data. **[a]** Using previously identified pathogenic variation from ClinVar, we use Jenks natural breaks optimization to partition each protein into regions (Methods). Hazard ratios are calculated for missense variants in each region, and the $\log_2$ fold change from the overall gene missense hazard ratio is listed by region. *PCSK9* includes one section with missing data (black). **[b]** Kaplan-Meier estimates (95% confidence intervals) for individuals with missense variants in regions defined as higher risk (red) or lower risk (blue) (logrank p-values). In genes where no variant met either the high or low-risk classification, the region with the highest or lowest risk was used in the comparison.

We establish a baseline hazard for all carriers of missense variants, regardless of coding position. The risk in each region is then compared to this baseline by $\log_2$ fold change (L2FC) **(Figure 2A)**. We then label segments with L2FC over 1.1 as higher-risk regions (HRR) and regions with L2FC under 0.9 as lower-risk regions (LRR). We find at least one region of elevated or decreased risk in all five genes analyzed **(Supplementary Figure 2)**. Further, we observe significant differences in clinical outcomes when comparing individuals with missense variants in HRRs versus LRRs **(Figure 2B)**. Inclusion of regional data improves model concordance and log-likelihood in all genes analyzed **(Supplementary Table 2)**.

In *BRCA2,* individuals with missense variants in HRRs develop breast cancer at a higher rate than those with missense variants in LRRs (Risk Ratio (RR)=1.68 [1.28, 2.07], logrank $p=4.0\times10^{-4}$). These regions may be particularly informative in genes where missense variants have different functional effects (*e.g.* gain vs loss-of-function). In *APOB*, we recover known pathogenic variants in exon 26 which increase risk (Region 11) and regions where LoF variants would be expected to lower risk (Regions 8-10) (RR=1.97 [1.53, 2.41], logrank p=0.0020, all HRRs vs LRRs).[37] Interestingly, we find four additional HRRs in *APOB* which were not previously associated with increased risk (Regions 1-3 and 7) (Age 60 RR = 1.36 [1.14, 1.58]

logrank p=0.044). This finding is replicated in our validation cohort (92,455 individuals from the DiscovEHR Collaboration) when comparing missense carriers in these regions to those without coding variants (Age 60 RR = 1.28 [1.01, 1.56] χ^2 p=0.044). The N-terminal region of *APOB* may play an important role in the protein assembly or secretion,[38] and further study is needed to validate these regions of increased clinical risk.

Consistent with prior work, we find that our regions of increased risk are broader than protein domains.[39] These regions provide risk estimates for larger portions of each gene (**Figure 3A**), and consequently for many more individuals **(Supplementary Table 3A-C)**. As found in a well-powered breast cancer study,[20] we find that individuals with *BRCA2* variants within a specified Pfam domain have no significant difference in RR compared to those with variants outside a specified domain (Age 65 RR=1.22 [0.86, 1.57]) (**Figure 3B, Supplementary Table 3B**), however we do find that they have significantly different longitudinal risk profiles (logrank p=0.01953, **Figure 3C**). We find that the RR conferred by our HRRs vs LRRs is stronger and more significant (RR=1.68 [1.28, 2.07], logrank p=0.0040), demonstrating the utility of this approach.

Regions identified as HRRs are aligned with specified Pfam domains which are known to confer increased risk (**Figure 3A**). We find no significant difference in risk between individuals with *BRCA2* missense variants within a named Pfam domain versus those with variants in the same regions outside of those Pfam domains (logrank p=0.35) **(Figure 3D)**, which extends to all other specified Pfam domains in *BRCA1* and *BRCA2* (**Supplementary Figure 3**).

Figure 3

[a]



[b]

Gene	Age 65 Risk Ratio - Pfam Domain / Non Pfam Domain	Age 65 Risk Ratio - Predicted Higher-Risk Region(s) / Lower-Risk Region(s)
APOB	0.95 [0.68, 1.22]	1.97 [1.53, 2.41]
BRCA1	0.78 [0.28, 1.28]	1.69 [1.15, 2.22]
BRCA2	1.22 [0.86, 1.57]	1.68 [1.28, 2.07]
LDLR	0.80 [0.34, 1.25]	1.13 [0.46, 1.80]
PCSK9	1.01 [0.17, 1.86]	1.14 [0.20, 2.09]

[c]



[d]



Figure 3: Comparison of regional boundaries to Pfam protein domains. [a] Schematic of the *BRCA2* transcript with Pfam protein domains (purple), predicted higher-risk regions (HRRs) (red), and lower-risk regions (LRR) (blue). **[b]** In the five genes analyzed, regional boundaries provide superior relative risks compared with Pfam protein domain boundaries. **[c]** Individuals with *BRCA2* variants within Pfam domains carry elevated risk for breast cancer (logrank p=0.0195). **[d]** The elevated-risk associated with Pfam domains is not limited to the domain itself. Specified Pfam domains partially overlap with predicted HRRs (Regions 8-10). We

find no significant difference in breast cancer risk among individuals with variants within specified Pfam domains vs. individuals with variants outside those domains within Regions 8-10.

Creating personalized clinical risk assessments

We next generated integrated risk scores for all UKB participants with variants in these nine genes, using a 10-fold cross-validated model for each gene. Each individual's hazard score represents the risk for a given disease relative to the overall population. Prior to this evaluation, variants were classified by an ABMGG board-certified laboratory geneticist blinded to any phenotypic information according to current clinical standards.[2] We generate scores for each individual blinded to this diagnostic data. Classification guidelines, cross validation strategy, and criteria for predictions are described in Methods.

As expected, we find individuals with variants described as pathogenic and likely pathogenic confer a significantly higher clinical risk (**Figure 4A, Supplementary Table 4A**). Notably, some individuals who carry pathogenic and likely pathogenic variants do not carry elevated overall risk scores. As expected, we also find a broad distribution of clinical risk conferred by VUSs, with many variants apparently conferring no or limited increased risk (**Supplementary Table 4B**).

Classifying the clinical risk attributable to VUS and P/LP variants

We classified patients with VUS into higher risk (HR) and lower risk (LR) groups based on their individual predicted hazard. We set a hazard threshold which maximizes the difference in clinical outcomes between HR and LR individuals **(Figure 4A, Methods)**. Overall, we find that our classifications are highly concordant with clinical outcomes, identifying groups with significantly different clinical risk ($p<10^{-5}$ in all genes) **(Figure 4B, top row)**. For individuals with missense variants in *BRCA1* and *BRCA2*, the predicted HR group has RR=3.71 [3.53, 3.90]

(logrank $p<10^{-51}$) for BC (Age 65), and for all FH genes the predicted HR group has RR=4.71 [4.50, 4.92] (logrank $p<10^{-65}$) for CAD (Age 65) **(Supplementary Figure 4A, Supplementary Table 4C)**. Similar risk ratios are observed between HR and LR groups when restricting solely to rare missense VUS carriers (RR=2.90 [2.60, 3.20] for BC, RR=4.52 [4.31, 4.73] for CAD), and when restricting to VUSs not previously reviewed by a clinical lab in ClinVar (RR=2.71 [2.26, 3.16] for BC, RR=3.75 [4.26, 3.25] for CAD) **(Supplementary Figure 4B-C).**

We next estimate the clinical risk for individuals who carry variants with a diagnostic classification of P/LP. Sufficient numbers of individuals with known pathogenic variants were available for comparisons in three genes (Methods). Using the same hazard thresholds as above, we classify each individual who carries a known pathogenic variant as HR or LR. Consistent with diagnostic classifications, we predict few women with pathogenic variants as being LR (*N*=5 in both *BRCA1* (18%) and *BRCA2* (10%)). However, among the 231 individuals with known pathogenic variants in *APOB*, *LDLR*, and *PCSK9,* we predict only 84 as being HR. These predicted HR individuals have a significantly increased risk of CAD than the P/LP carriers classified as LR (RR=3.70 [2.92, 4.48], logrank $p=1.4\times10^{-4}$). **Notably, 64% of individuals who carry known pathogenic FH variants are not predicted to have high risk of CAD**. We find no significant difference in CAD risk between these 147 individuals (N=147/231) compared to individuals with no variant in these genes (logrank p=0.683) or when compared to LR VUS carriers (logrank p=0.172) **(Figure 4C)**.

We find significant differences in sex, family history, and polygenic risk scores between individuals with pathogenic variants who are classified as higher or lower risk (**Supplementary Table 5)**, however we find no significant difference in adjusted LDL cholesterol levels

(Supplementary Table 6). These results extend to the gene level: individuals with pathogenic variants predicted as HR do not have significantly different clinical risk from VUS carriers who are predicted as HR in each of the three genes analyzed (**Figure 4B, bottom row**). Similarly, we find no significant difference in clinical risk between VUS carriers predicted as LR compared with synonymous variant carriers in the same score ranges in any of the five genes (**Figure 4B center row**). Many of the same comparisons also hold when comparing clinical outcomes solely among missense VUS carriers and also among those who carry variants previously unreported in ClinVar (**Supplementary Figure 5**) and for other separations **(Supplementary Figure 6).**

We provide an online tool that generates personalized estimates of lifetime and age-specific risk assessments for variants in each of these nine genes (https://clintegrate.herokuapp.com/), as well as a downloadable python package to make estimates of clinical risk (https://github.com/j-fife/clintegrate/).

Figure 4

[a]


BRCA1
BRCA2
LDLR
APOB
PCSK9
Predicted Partial Hazard
VUS
P/LP
Synonymous

[b]


BRCA1
BRCA2
LDLR
APOB
PCSK9
p-value < 10^{-16}
p-value < 10^{-35}
p-value < 10^{-10}
p-value < 10^{-53}
p-value < 10^{-5}
p-value = 0.06624
p-value = 0.50247
p-value = 0.19964
p-value = 0.54898
p-value = 0.88809
p-value = 0.80634
p-value = 0.95937
p-value = 0.7163
Proportion Unaffected by Breast Cancer
Proportion Unaffected by CAD
Age
Predicted High Risk VUS
Predicted Low Risk VUS
Synonymous
Predicted High Risk P/LP

[c]


Classifying CAD risk for individuals with known pathogenic variants in *APOB*, *LDLR*, and *PCSK9*
p-value = 0.00014
p-value = 0.68286
p-value = 0.17188
Proportion Unaffected by CAD
Age
Predicted High Risk P/LP
Predicted Low Risk P/LP
No Variant
Predicted Low Risk VUS

Figure 4: Clinical risk classifications for UK Biobank patients with variants of uncertain significance (VUS). [a] Each point represents an individual's hazard prediction. High and low risk cutoffs (cyan and navy colorings) are determined by the maximum difference in clinical outcomes (measured by logrank p-value) among individuals above and below the threshold value. Sufficient laboratory classified P/LP variants are present in three genes, however we create risk thresholds for all genes which contain sufficient numbers of individuals with VUS and each phenotype (see Methods). **[b]** Risk thresholds significantly separate individuals with high and low clinical risk for breast cancer or coronary artery disease (CAD) in all five genes examined ($p < 10^{-7}$ in all cases). Additionally, we observe no significant difference in risk when comparing individuals with VUS who fall below the threshold, and individuals with synonymous variants. Further, those individuals with lab-classified P/LP variants above the risk threshold did not develop the associated condition at higher rates than those with predicted HR VUS in the same score range. **[c]** Our model predicts many individuals with pathogenic variants related to FH to be at low risk for CAD despite their variant status. We find significant differences in clinical risk between individuals who are predicted as HR vs. LR, and observe no significant difference between low-risk P/LP carriers and those who carry no variant, or are predicted LR VUS carriers.

Validation of risk classification in a second, independent biobank

We validate our predictions of clinical risk on an independent set of 92,455 individuals from the MyCode cohort at Geisinger Health System with available exome sequence and clinical data (Methods). Using the predictive models generated for each gene using the UKB dataset, we estimate the clinical risk for each patient with non-synonymous coding variants in the three FH and two BC genes previously evaluated. We find statistically significant differences in predicted hazards among individuals in both CAD or BC by age 65 **(Figure 5A-B**). Further, patients who are predicted to have HR are significantly enriched in early onset phenotypes (two sample χ^2) **(Table 5C)**. For all individuals who carry variants in any gene associated with CAD or BC, we see large differences in development among those predicted as high-risk for breast cancer (χ^2 $p=9.9\times10^{-4}$, RR=3.92 [3.18, 4.66]) and for CAD (χ^2 $p=3.72\times10^{-16}$, RR=2.39 [2.18, 2.6]) (**Figure 5D)**. Though there are limited numbers of novel variants in the MyCode cohort which are not

observed in the UKB, we analyze the relative risks and hazards for those variants in each gene (**Supplementary Table 7**).

Figure 5

[a]

Model-predicted scores by phenotype status at age 65 among non-synonymous carriers in the validation cohort



[b]

Predicted hazards by phenotype status among carriers of nonsynonymous variants by age 65 in validation cohort

Gene	Phenotype	Avg. hazard in individuals with phenotype (95% CI)	Avg. hazard in individuals without phenotype (95% CI)	Mann-Whitney U p-value	Individuals with phenotype by 65	Individuals without phenotype by 65
APOB	CAD	2.56 [2.19, 2.93]	1.51 [1.39, 1.63]	1.23×10^{-11}	187	925
LDLR	CAD	3.76 [2.87, 4.66]	1.49 [1.21, 1.78]	6.17×10^{-10}	71	153
PCSK9	CAD	4.19 [2.09, 6.28]	2.24 [1.73, 2.76]	0.016	15	81
BRCA1	BC	2.39 [0.89, 3.88]	1.16 [0.98, 1.34]	0.0067	22	317
BRCA2	BC	1.45 [0.98, 1.92]	1.06 [0.98, 1.14]	0.011	20	424

[c]

Classification accuracy for carriers of non-synonymous variants by age 65 in validation cohort by gene

Gene	Phenotype	Partial hazard threshold	Individuals with phenotype above threshold	Individuals with phenotype below threshold	Age 65 Risk Ratio (95% CI)	χ^2 p-value
APOB	CAD	2.1	86 / 295	101 / 817	2.36 [2.1, 2.61]	7.11×10^{-11}
LDLR	CAD	2.8	31 / 51	40 / 173	2.63 [2.28, 2.98]	9.16×10^{-7}
PCSK9	CAD	3.0	8 / 28	7 / 68	2.78 [1.86, 3.69]	0.053
BRCA1	BC	2.5	5 / 21	17 / 318	4.45 [3.56, 5.35]	0.0041
BRCA2	BC	2.3	2 / 17	18 / 427	2.79 [1.41, 4.17]	0.38

[d]

Classification accuracy for carriers of non-synonymous variants by age 65 in validation cohort by phenotype

Phenotype	Genes	Individuals with phenotype above threshold	Individuals with phenotype below threshold	Age 65 Risk Ratio	χ^2 p-value
BC	*BRCA1, BRCA2*	7 / 38	35 / 745	3.92 [3.18, 4.66]	9.9×10^{-4}
CAD	*APOB, LDLR, PCSK9*	125 / 374	148 / 1058	2.39 [2.18, 2.6]	3.72×10^{-16}

Figure 5: Prediction validation on phenotypic outcomes in a second biobank. [a-b] Validation of hazard scores in an external cohort. Gene-based predictive models were fit using data from patients in the UKB cohort and validated using 92,455 individuals from the Geisinger DiscovEHR cohort. Using the gene-based models generated from UKB participants, estimates of clinical risk are generated for individuals in the validation cohort. We find individuals with early-onset coronary artery disease (CAD) or breast cancer (BC, before age 65) have significantly higher predicted hazards than those unaffected by age 65 (Mann-Whitney U). **[c-d]** We find significant enrichment of early-onset CAD or BC cases in the validation cohort as determined by χ^2 p-value, among individuals receiving scores greater than the classification threshold generated from the UKB model by gene, and by phenotype.

Discussion

Despite the established causality of these genes, it is challenging to assess the clinical risk of most rare variants identified in prospectively screened patients.[40] These patients without an indication for testing have different risk profiles which cannot be accurately modeled by previously described clinical variation. We have developed a framework to provide integrated risk estimates for patients who carry germline variants derived from population screening data.

These predictions are highly concordant with clinical outcomes in both the UKB (under cross-validation) as well as in a large independent validation cohort.

These findings suggest that restricting to variant-level data in clinical risk assessments may be limiting the full potential of genomic medicine. Based on the inherent complexities in variant interpretation and the potential for harm from inaccurate interpretations, the ACMG and the Association for Molecular Pathology have provided guidelines which focus on classification at the variant level.[2] These and other guidelines related to interpretation[41] and reporting of secondary findings[42] discourage the disclosure of VUS on the basis of their limited evidence, placing the disclosure emphasis on previously identified pathogenic variants in prospectively screened patients.

Here, we are able to identify individuals who carry previously unclassified variants who have significantly increased clinical risk, which could be used to improve clinical management. Conversely, we also find individuals with known pathogenic variants who have no increased risk of developing a disorder. Disclosures of such incorrect or inconsistent risk interpretations can have serious clinical and/or sociological consequences, either through unnecessary surveillance, incorrect clinical action taken due to a missing or incorrect lab result,[43] or in irreversible prophylactic surgical decision making.[44] In one study, over 20% of women who received a VUS in *BRCA1* or *BRCA2* opted to receive a mastectomy or bilateral salpingo-oophorectomy for cancer risk reduction. Ultimately not all of these surgeries were necessary—44.8% of these VUS were later classified as benign.[44]

Our findings suggest that integrated clinical predictions for individuals who carry VUS should be evaluated prospectively to determine whether they have clinical utility for guiding risk management decisions when compared with existing standard of care. This may include expanding assessments and disclosure of high risk VUS related to secondary findings from

patients who may already be undergoing clinical sequencing, or the identification of patients within medical systems who may not be adequately managed (*e.g.* those with elevated LDL cholesterol levels despite a high risk FH variant). Additionally, surveillance or treatment strategies could first be studied retrospectively in biobanks to determine whether there is sufficient evidence to prospectively study or alter clinical guidelines.

The syndromes in this study have both monogenic and polygenic risk, which makes them suitable for integrated predictions which consider both factors. Importantly, we note that previous studies of polygenic risk have found limitations to the applicability of polygenic risk estimates in non-European populations,[45] indicating the urgent need to expand study cohorts and to develop improved trans-ethnic risk prediction methods. Clinical translation of these results will rely on broader validation and evaluation of these methods, and to populations beyond the UK. Additionally, the biobanks in this study may have biases due to ascertainment or censoring.

By building each model by gene, we fit the unique regional context and risk profile for variants in each protein. As biobank sequencing cohorts expand, we expect our resolution to improve for regional estimates, and to have sufficient statistical power to model interactions between monogenic and polygenic risk. Future work should integrate additional established behavioral and clinical risk factors for each syndrome. Larger panels of genes will require sufficient prevalence of each disorder attributable to each gene, validated polygenic risk scores, and other individual-level predictive features.

As population sequencing efforts expand, it is critical to further improve and personalize predictions of clinical risk. This is particularly important in asymptomatic individuals with no clinical risk factors or family history, as many variants in known disease genes may not confer risk or be completely penetrant. Biobanks and population cohorts are now sufficiently powered

to advance genomic medicine through the development of standards that optimize surveillance, counseling, and therapeutic interventions.

Methods

Study design, setting and participants

The UKB is a prospective cohort of 500,000 individuals recruited between 2006 and 2010 of ages 40-69 years.[10] 200,625 participants with exome sequencing data were included in this analysis. Analysis of the UKB data was approved by the Mass General Brigham Institutional Review Board (Protocol 2013P001840). Work was performed under UKB application #7089. Family history of disease in parents and siblings was reported by participants using a structured assessment tool at the time of enrollment. From participant survey data, we identified individuals with a family history of three common, related phenotypes (reported as heart disease for FH genes, breast cancer for HBOC genes, and bowel cancer for Lynch syndrome genes). Adjustments were not made for family size. LDL cholesterol concentrations were assessed at the time of enrollment as part of the study protocol. To estimate untreated values for LDL cholesterol, measured values for participants reporting use of lipid-lowering medications were adjusted in accordance with average impact on LDL cholesterol levels, as performed previously.[21] Polygenic risk was calculated for each patient using previously validated scores for each of the three disorders,[23,46,47] using ancestry-corrected reference distributions for each score.[48]

Exome sequencing and variant annotation

Exome sequencing was performed for UKB participants as previously described.[10] Variant allele frequencies were estimated from the Genome Aggregation Database (gnomAD v2.1 exomes

N=125,748). Variants were included with population maximum allele frequencies of <=0.001 (N=9,042) (Ensembl gnomAD plugin)[49] or if not present in gnomAD (N=6,715). The canonical functional consequence of each variant was calculated using Variant Effect Predictor (v99).[50] Additionally, GERP, PhyloP, population allele frequencies, and CADD scores (Ensembl REST API v15.0)[49] were included for each variant where available, as well as variant CpG and transition/transversion status.[51] From VEP, "CADD_raw", "GERP++_rs", and "phyloP100way_vertebrate" scores are listed as CADD, GERP, and phyloP in the manuscript. CpG context was obtained from PolyPhen-2 v2.2.3.[52] Variants which are non-PASS quality in gnomAD were excluded, as well as any variants in low complexity regions, segmental duplications, or other regions known to be challenging for next generation sequencing alignment or calling.[17] Variant functional consequences are calculated for the canonical transcript, and include synonymous, missense, or predicted LOF variants. The predicted LOF category includes frameshift, stop gained, start gained, and canonical splice-site variants. Non-coding variants outside of essential splice sites were not considered in the analysis.

Clinical diagnostic assessment of variants

A board-certified laboratory geneticist (blinded to any patient phenotypic information) classified the pathogenicity of observed variants in the study genes according to current clinical standards. The nine study genes included three related to familial hypercholesterolemia (*APOB*, *LDLR*, and *PCSK9*), two related to breast cancer (*BRCA1* and *BRCA2*), and four related to Lynch syndrome (*MLH1, MSH2, MSH6,* and *PMS2*). Clinical variant assessments were made for all rare, non-synonymous variants (gnomAD population maximum allele frequency <=0.001), following the ACMG/AMP guidelines for variant assessment and best practices.[2] All variants

meeting these criteria which had not been previously classified as P/LP/LB/B were classified as VUS for this analysis.

Individuals with multiple variants in the same gene with different annotations of P/LP/VUS were always included in the most severe category in descending order: P, LP, and VUS. Synonymous variants were grouped separately, and not labeled VUS.

Clinical endpoints

The primary clinical endpoints were specific to each condition -- coronary artery disease (CAD) for familial hypercholesterolemia, breast cancer (BC) for HBOC syndrome, and colorectal cancer for Lynch syndrome. Case definitions for CAD, BC, and colorectal cancer were defined in the UKB using a combination of self-reported data confirmed by trained healthcare professionals, hospitalization records, and national procedural, cancer, and death registries, previously described at the disorder level.[13] Estimated untreated levels obtained using adjustments for lipid-lowering therapies were used in analyses, as described previously.[21]

Predictive models and feature selection for each gene

The age-dependent hazards for each disease were generated by comparing individuals affected by each condition to those unaffected, using a Cox proportional-hazard model for each gene and condition. Covariates include genetic principal components 1-4, CADD, gnomAD population maximum allele frequency, GERP, phyloP, transition/transversion, CpG/non-CpG context, variant functional consequence (synonymous, missense, predicted LOF), sex, family history, and polygenic risk score, with the predictive model standardized to the average of each of the covariates across all individuals as the baseline prediction. Statistical analyses were performed

using the python lifelines survival analysis package (v0.23.9).[53] Hazard predictions for individuals are generated using a 10-fold cross-validation process, where predictions are made for each 10% by training a separate Cox model using the remaining 90% of the participants.

A predictive model was developed for each gene separately. Features were included if univariate regression was statistically significant ($p < 0.05$) as a predictor for each phenotype, or if inclusion of the feature resulted in an improvement in model concordance of at least 0.01 when added to a model with all univariate significant features. Additionally, categorical variables related to functional consequence were always included (synonymous, missense, predicted LoF).

For individuals with more than one variant in a gene, the variant with the most severe functional annotation is analyzed. If this led to a patient carrying two variants of the same functional category, the variant labeled P/LP through LMM annotation was prioritized when applicable. If a patient carried multiple variants with the same functional consequence and neither had P/LP classification, the variant with the highest CADD score is included for analysis. If variants have the same CADD score, the variant with the lowest allele frequency is selected. Patients are included in each model regardless of whether they carry a variant in each gene to establish a baseline for incidence excluding variant-level factors. Individuals without variants in each gene have all variant-level features either assigned to zero or to the least severe value for each feature.

For each gene's predictive model we removed all individuals with coding variants in other genes related to the same condition. For the *BRCA1* and *BRCA2* models examining risk for breast

cancer, males were excluded from all analyses. Individuals with missing information regarding age, age of onset, or presence of the condition were not included in any analyses.

VUS and P/LP comparisons by gene

In selecting genes to compare across annotation classes, we restrict to genes with more than 15 cases of the disorder in individuals with variants in the gene, and more than 5 unique variants designated as P/LP observed in the patient set after patient and variant filtering described previously. In *APOB* only one variant, and in *PCSK9* only three variants met our criteria. These genes were not compared in certain parts of Figure 4, but their comparisons can be found in Supplementary Figure 6. In all survival analyses related to outcomes across classes (Figure 4), we excluded individuals over age 70, and excluded individuals with coding variants in other genes related to the same disorder. In Figure 4C we use a cutoff of 3.0 predicted partial hazard when designating low-risk VUS carriers. This was due to the abundance of carriers in *APOB* when compared to *LDLR and PCSK9. APOB* has a much lower threshold, skewing the overall risk-makeup of the VUS group.

Filtering variants used in regional boundary generation

To generate protein boundaries for differential risk stratification, we partitioned each gene restricted to pathogenic variants in ClinVar. Single nucleotide missense variants were included for analysis from ClinVar (June, 2019) which were non-canonical-splice affecting and non-terminating. Only pathogenic and likely pathogenic variants were included which had no conflicting interpretations. Reports of pathogenicity were all treated as a positional input (*e.g.* a variant with 3 reports of pathogenicity were included as three values for the same position).

Regions were defined based on the result of Jenks natural breaks optimization for varying numbers of sections. We set the number of regions based on the length of the coding sequence as the floor of one per thousand base pairs (*e.g.* 13 regions for *APOB*: 13,689bp, 5 regions for *BRCA1*: 5,589bp). For genes with fewer than 5,000bp we set a minimum number of 5 regions. In *PCSK9* a portion of the coding sequence was not covered in the exome sequencing data. We treat this protein region as missing, and separate the remaining 1,672bp into four regions using the Jenks optimization method (black section, **Figure 2A**). Four of the nine genes (*MLH1*, *MSH2*, *MSH6*, *PMS2*) did not have sufficient individuals with colorectal cancer and missense variants in the UKB to reliably determine differences in risk by region.

For comparisons of regions with increased risk versus those with decreased risk, we first compared the highest risk region to the lowest risk region and measured whether there was a significant difference in clinical risk. If not, the next highest- or lowest-risk regions were added to the high- or low- risk regions to optimize logrank p-value for separating clinical risk, or until all regions were exhausted. For all genes evaluated, the optimal logrank p-value is reported.

We provide a hypothesis-free approach to modeling regional boundaries which may confer differential risk for missense variants. Methods to infer the impact of variants from selective constraint have advanced considerably, but do not yet have high spatial resolution for broad numbers of proteins. We instead develop regional boundaries using the abundant diagnostic data for pathogenic variants in these genes (rather than in combination with putatively neutral variation). Statistical tests of heterogeneity demonstrate that inclusion of our regional boundaries improves model concordance.

Statistical Tests

We use the logrank test when determining differences in clinical risk for each disorder among different groups in the UKB due to the availability of age of onset in addition to participants' current age. When measuring differences in clinical risk in the validation cohort, the chi-squared test at a specific age is used, as age of onset was unavailable. While risk plots include participants through age 70, data for these statistical comparisons was not age restricted. All risk ratios (RR) are taken at age 65 unless otherwise specified. All confidence intervals reported are 95%. Logrank p-values are generated using the python package lifelines v0.23.9.[53] Chi square and Mann-Whitney U tests were performed using scipy v1.4.1.[54] Mann-Whitney U p-values are two-sided. Additional data processing, computation, and statistical tests were performed using NumPy v1.17.3[55] and pandas v1.1.5.[56] Figures were made using Matplotlib v3.1.1[57] and seaborn v0.9.0.[58] Box plots show the median, and quartile ranges as default parameters to seaborn, data determined by seaborn's method as outliers are not shown on boxplots but are shown in the underlying plots of points.

Criteria For Geisinger Biobank Variant Filtering and Individual-level features

Similar to filtering on UKB participants, when evaluating a gene's predictive model we restrict it to individuals without non-synonymous coding variants in the other genes related to the condition. For individuals with multiple non-synonymous coding variants in the same gene, values for the variant included in the model are selected in the same fashion as selecting variants among UKB participants. As expected based on clinical ascertainment, we found differences in disorder incidence between Geisinger Biobank and UKB, and no adjustment for incidence was done when making predictions on Geisinger Biobank participants **(Supplementary Table 8).**

Data Availability

Pretrained models, usage examples, and documentation of our downloadable python module can be found here (https://github.com/j-fife/clintegrate/). Precomputed feature vectors for all SNVs in the analyzed genes are also available in the repository.

References

1. Green, E. D. *et al.* Strategic vision for improving human health at The Forefront of Genomics. *Nature* **586**, 683–692 (2020).
2. Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.* **17**, 405–423 (2015).
3. Rehm, H. L. *et al.* ClinGen — The Clinical Genome Resource. *N. Engl. J. Med.* **372**, 2235–2242 (2015).
4. Goodrich, J. K. *et al.* Determinants of penetrance and variable expressivity in monogenic metabolic conditions across 77,184 exomes. *Nat. Commun.* **12**, 3505 (2021).
5. Cassa, C. A., Tong, M. Y. & Jordan, D. M. Large numbers of genetic variants considered to be pathogenic are common in asymptomatic individuals. *Hum Mutat* (2013) doi:10.1002/humu.22375.
6. Forrest, I. S. *et al. Ancestrally and Temporally Diverse Analysis of Penetrance of Clinical Variants in 72,434 Individuals*. http://medrxiv.org/lookup/doi/10.1101/2021.03.11.21253430 (2021) doi:10.1101/2021.03.11.21253430.
7. Friebel, T. M., Domchek, S. M. & Rebbeck, T. R. Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis. *JNCI J. Natl. Cancer Inst.* **106**, (2014).
8. Saadatagah, S. *et al.* Genetic basis of hypercholesterolemia in adults. *Npj Genomic Med.* **6**, 1–7 (2021).
9. Fahed, A. C. *et al.* Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions. *Nat. Commun.* **11**, 3635 (2020).
10. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.

Nature **562**, 203–209 (2018).

11. Miller, D. T. *et al.* ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). *Genet. Med.* 1–10 (2021) doi:10.1038/s41436-021-01172-3.
12. Landrum, M. J. *et al.* ClinVar: Public archive of relationships among sequence variation and human phenotype. *Nucleic Acids Res.* **42**, (2014).
13. Patel, A. P. *et al.* Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History. *JAMA Netw. Open* **3**, e203959 (2020).
14. Natarajan, P. *et al.* Aggregate penetrance of genomic variants for actionable disorders in European and African Americans. *Sci. Transl. Med.* **8**, 364ra151-364ra151 (2016).
15. Dewey, F. E. *et al.* Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. *Science* **354**, (2016).
16. Tong, M. Y., Cassa, C. A. & Kohane, I. S. Automated validation of genetic variants from large databases: ensuring that variant references refer to the same genomic locations. *Bioinformatics* **27**, 891–893 (2011).
17. Zook, J. Genome In A Bottle - Genome Stratifications. (2020) doi:10.18434/M32190.
18. Harrison, S. M. & Rehm, H. L. Is ‘likely pathogenic’ really 90% likely? Reclassification data in ClinVar. *Genome Med.* **11**, 72 (2019).
19. Bonadies, D. C. *et al.* Adverse events in cancer genetic testing: the third case series. *Cancer J. Sudbury Mass* **20**, 246–253 (2014).
20. Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women. *N. Engl. J. Med.* **384**, 428–439 (2021).

21. Khera, A. V. *et al.* Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. *J. Am. Coll. Cardiol.* **67**, 2578–2589 (2016).
22. Tutt, A. N. J. *et al.* Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. *N. Engl. J. Med.* **384**, 2394–2405 (2021).
23. Khera, A. V. *et al.* Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nat. Genet.* **50**, 1219–1224 (2018).
24. Oetjens, M. T., Kelly, M. A., Sturm, A. C., Martin, C. L. & Ledbetter, D. H. Quantifying the polygenic contribution to variable expressivity in eleven rare genetic disorders. *Nat. Commun.* **10**, 4897 (2019).
25. Gallagher, S. *et al.* Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. *JAMA Netw. Open* **3**, e208501 (2020).
26. Barnes, D. R. *et al.* Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genet. Med.* **22**, 1653–1666 (2020).
27. Cooper, G. M. *et al.* Distribution and intensity of constraint in mammalian genomic sequence. *Genome Res.* **15**, 901–13 (2005).
28. Davydov, E. V. *et al.* Identifying a High Fraction of the Human Genome to be under Selective Constraint Using GERP++. *PLOS Comput. Biol.* **6**, e1001025 (2010).
29. Kircher, M. *et al.* A general framework for estimating the relative pathogenicity of human genetic variants. *Nat. Genet.* **46**, 310–5 (2014).
30. Kryukov, G. V., Pennacchio, L. A. & Sunyaev, S. R. Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. *Am J Hum Genet* **80**, 727–739 (2007).

31. Gussow, A. B., Petrovski, S., Wang, Q., Allen, A. S. & Goldstein, D. B. The intolerance to functional genetic variation of protein domains predicts the localization of pathogenic mutations within genes. *Genome Biol.* **17**, 9 (2016).
32. Samocha, K. E. *et al.* Regional missense constraint improves variant deleteriousness prediction. *bioRxiv* (2017).
33. Sivley, R. M. *et al.* Comprehensive Analysis of Constraint on the Spatial Distribution of Missense Variants in Human Protein Structures. *bioRxiv* (2017).
34. Cassa, C. A. *et al.* Estimating the selective effects of heterozygous protein-truncating variants from human exome data. *Nat. Genet.* **49**, 806–810 (2017).
35. Dines, J. N. *et al.* Systematic misclassification of missense variants in BRCA1 and BRCA2 “coldspots”. *Genet. Med.* **22**, 825–830 (2020).
36. Cohen, J. C., Boerwinkle, E., Mosley, T. H. & Hobbs, H. H. Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease. *N. Engl. J. Med.* **354**, 1264–1272 (2006).
37. Peloso, G. M. *et al.* Rare Protein-Truncating Variants in APOB, Lower Low-Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease. *Circ. Genomic Precis. Med.* **12**, e002376 (2019).
38. Shelness, G. S. & Thornburg, J. T. Role of intramolecular disulfide bond formation in the assembly and secretion of apolipoprotein B-100-containing lipoproteins. *J. Lipid Res.* **37**, 408–419 (1996).
39. Rebbeck, T. R. *et al.* Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA* **313**, 1347–1361 (2015).
40. Whiffin, N. *et al.* Using high-resolution variant frequencies to empower clinical genome interpretation. *Genet. Med.* **19**, 1151–1158 (2017).

41. Murray, M. F. *et al.* DNA-based screening and population health: a points to consider statement for programs and sponsoring organizations from the American College of Medical Genetics and Genomics (ACMG). *Genet. Med.* **23**, 989–995 (2021).
42. Kalia, S. S. *et al.* Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. *Genet. Med.* **19**, 249–255 (2017).
43. Manchanda, R. *et al.* Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. *BJOG Int. J. Obstet. Gynaecol.* **118**, 814–824 (2011).
44. Murray, M. L., Cerrato, F., Bennett, R. L. & Jarvik, G. P. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. *Genet. Med. Off. J. Am. Coll. Med. Genet.* **13**, 998–1005 (2011).
45. Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health disparities. *Nat. Genet.* **51**, 584–591 (2019).
46. Mavaddat, N. *et al.* Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *Am. J. Hum. Genet.* **104**, 21–34 (2019).
47. Huyghe, J. R. *et al.* Discovery of common and rare genetic risk variants for colorectal cancer. *Nat. Genet.* **51**, 76–87 (2019).
48. Khera, A. V. *et al.* Whole-Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial Infarction. *Circulation* **139**, 1593–1602 (2019).
49. Yates, A. *et al.* The Ensembl REST API: Ensembl Data for Any Language. *Bioinformatics* **31**, 143–145 (2015).
50. The Ensembl Variant Effect Predictor | Genome Biology | Full Text.

https://genomebiology.biomedcentral.com/articles/10.1186/s13059-016-0974-4.

51. Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting functional effect of human missense mutations using PolyPhen-2. *Curr Protoc Hum Genet* **Chapter 7**, Unit7 20 (2013).
52. Adzhubei, I. A. *et al.* A method and server for predicting damaging missense mutations. *Nat Methods* **7**, 248–249 (2010).
53. Cameron Davidson-Pilon *et al. CamDavidsonPilon/lifelines: v0.25.9*. (Zenodo, 2021). doi:10.5281/zenodo.4505728.
54. Virtanen, P. *et al.* SciPy 1.0: fundamental algorithms for scientific computing in Python. *Nat. Methods* **17**, 261–272 (2020).
55. Harris, C. R. *et al.* Array programming with NumPy. *Nature* **585**, 357–362 (2020).
56. McKinney, W. Data Structures for Statistical Computing in Python. in 56–61 (2010). doi:10.25080/Majora-92bf1922-00a.
57. Hunter, J. D. Matplotlib: A 2D Graphics Environment. *Comput. Sci. Eng.* **9**, 90–95 (2007).
58. Waskom, M. L. seaborn: statistical data visualization. *J. Open Source Softw.* **6**, 3021 (2021).

Supplementary Data

Supplementary Table 1

Hazard ratio (95% CI) for univariate regressions on model features

Gene	Condition	CADD ≥ 5.0 (95% CI)	GERP ≥ 4.0 (95% CI)	phyloP ≥ 3.0 (95% CI)	Allele Frequency ≦10^{-4} (95% CI)
BRCA1	Breast Cancer	7.71 [5.32, 11.17]***	1.3 [0.96, 1.76]	1.26 [0.84, 1.88]	1.22 [0.97, 1.53]
BRCA2	Breast Cancer	5.48 [4.36, 6.88]***	1.06 [0.82, 1.38]	1.17 [0.89, 1.54]	1.44 [1.24, 1.66]***
APOB	Coronary Artery Disease	0.36 [0.14, 0.96]*	1.17 [1.0, 1.37]*	1.17 [0.98, 1.41]	0.89 [0.77, 1.03]
LDLR	Coronary Artery Disease	6.2 [2.78, 13.81]***	1.5 [1.12, 2.02]*	1.53 [1.07, 2.17]*	1.4 [1.08, 1.82]*
PCSK9	Coronary Artery Disease	2.0 [0.5, 8.0]	1.79 [1.06, 3.02]*	1.36 [1.0, 1.86]	1.18 [0.84, 1.65]
MLH1	Colorectal Cancer	N/A	1.74 [1.26, 2.41]**	1.73 [1.25, 2.4]**	2.54 [1.74, 3.71]***
MSH2	Colorectal Cancer	N/A	1.07 [0.73, 1.58]	1.03 [0.69, 1.52]	0.8 [0.45, 1.41]
MSH6	Colorectal Cancer	1.15 [0.62, 2.14]	0.99 [0.63, 1.55]	0.84 [0.59, 1.19]	0.98 [0.69, 1.4]
PMS2	Colorectal Cancer	3.77 [0.94, 15.07]	0.74 [0.28, 1.97]	0.86 [0.36, 2.08]	1.16 [0.43, 3.08]

Gene	Condition	Family History	PRS ≥ 2.5 (95% CI)	Sex=Male	Missense	Predicted LoF
BRCA1	Breast Cancer	1.8 [1.68, 1.92]***	2.5 [2.19, 2.86]***	N/A	0.97 [0.82, 1.16]	7.31 [5.07, 10.52]***
BRCA2	Breast Cancer	1.81 [1.7, 1.93]***	2.52 [2.21, 2.87]***	N/A	0.99 [0.86, 1.15]	5.31 [4.24, 6.65]***
APOB	Coronary Artery Disease	1.77 [1.69, 1.85]***	3.29 [2.82, 3.83]***	4.86 [4.59, 5.14]***	1.07 [0.96, 1.19]	0.34 [0.13, 0.91]*
LDLR	Coronary Artery Disease	1.78 [1.69, 1.87]***	3.22 [2.74, 3.79]***	5.42 [5.09, 5.77]***	1.32 [1.07, 1.63]*	6.61 [2.97, 14.72]***
PCSK9	Coronary Artery Disease	1.75 [1.67, 1.84]***	3.2 [2.73, 3.75]***	4.88 [4.6, 5.17]***	1.62 [1.17, 2.25]**	2.26 [0.57, 9.04]
MLH1	Colorectal Cancer	1.8 [1.6, 2.01]***	1.26 [0.75, 2.13]	1.38 [1.25, 1.51]***	1.74 [1.22, 2.48]**	N/A
MSH2	Colorectal Cancer	1.78 [1.59, 2.0]***	1.18 [0.68, 2.03]	1.37 [1.25, 1.5]***	0.78 [0.49, 1.24]	9.49 [4.26, 21.15]***
MSH6	Colorectal Cancer	1.77 [1.58, 1.99]***	1.17 [0.68, 2.01]	1.37 [1.25, 1.5]***	1.16 [0.83, 1.62]	1.15 [0.62, 2.14]
PMS2	Colorectal Cancer	1.76 [1.57, 1.97]***	1.19 [0.69, 2.06]	1.36 [1.24, 1.49]***	1.2 [0.54, 2.67]	3.77 [0.94, 15.07]

*** $p < 0.0005$
**$p < 0.005$
*$p < 0.05$

Supplementary Table 1: We fit a Cox Proportional Hazards model on each gene's predictive features separately. We find varying levels of risk associated with variant level features (CADD, GERP, etc.) as well as varying levels of risk associated with having variants in these genes whether they be Missense variants of predicted LOF variants (frameshift, splice-site altering, nonsense). Entries labeled N/A were caused by convergence errors when regressing on that feature due to lack of differential clinical outcomes among groups with and without that feature. In the case of *BRCA1* and *BRCA2* sex was not used as a feature since their predictive models only include women. Slight differences in individual-level features in genes related to the same condition (family history, sex, PRS) are do to exclusions of patients with coding variants in other associatd genes (see Methods) leading to a different set of patients for each gene model.

Supplementary Table 2

Model predictive power with regional information included

Predictive Model	Log-likelihood ratio test Regions Included	Log-likelihood ratio test Regions Excluded	Difference	Test of heterogeneity χ^2 p-value
APOB	6185.27	6174.16	11.11	0.035
BRCA1	1410.53	1406.66	3.87	0.10
BRCA2	1471.85	1459.33	12.52	0.0030
LDLR	6195.63	6192.82	2.81	0.23
PCSK9	6164.06	6162.58	1.48	0.40

Supplementary Table 2: We fit predictive models with and without regional definitions as parameters. In genes where significant logrank p-value was not reached through a high and low risk regional comparison (*BRCA1, LDLR*), test of heterogeneity χ^2 p-value also significant. Log-Likelihood ratio test also indicated better fit of the predictive models in all five genes examined.

Supplementary Table 3

[a] Missense Variant Carriers in Pfam Domains vs. High and Low Risk Region Partitions

Gene	Pfam Missense Carriers	Non-Pfam Missense Carriers	High-Risk Region Carriers	Low-Risk Region Carriers
APOB	1165	3446	504	723
BRCA1	232	977	303	320
BRCA2	339	1416	682	502
LDLR	724	332	191	293
PCSK9	230	96	122	107

[b] Missense Variant Carriers and Rate Regions Defined by Our Partitions

***BRCA2* Partition Region**	**Individuals with Non-Synonymous Variants**	**Breast Cancer Cases among Individuals with Non-Synonymous Variants**	**Breast Cancer Rate**
Region 1	363	15	0.041
Region 2	566	33	0.058
Region 3	407	25	0.061
Region 4	412	33	0.080
Region 5	283	12	0.042
Region 6	382	14	0.037
Region 7	280	19	0.068
Region 8	314	25	0.080
Region 9	147	9	0.061
Region 10	359	26	0.072

[c] Missense Variant Carriers and Onset Regions Defined by Our Partitions

***BRCA2* Pfam Domain**	**Individuals with Non-Synonymous Variants**	**Breast Cancer Cases among Individuals with Non-Synonymous Variants**	**Breast Cancer Rate**
Helical	259	20	0.077
OB1	72	6	0.083
Tower	46	3	0.065
OB3	119	11	0.092
Unspecified	190	14	0.074

[d] Breast Cancer development in high-risk partition regions vs. pfam domains

***BRCA2* Region**	**Individuals with Non-Synonymous Variants**	**Breast Cancer Cases among Individuals with Non-Synonymous Variants**	**Breast Cancer Rate**
All specified Pfam Domains	686	54	0.079
Regions 4,7,8,10	1365	103	0.076

Supplementary Table 3: In the five genes analyzed, Pfam domains in *BRCA2* showed the most signal in terms of individuals with variants in these domains, and signal measured by the Cox Model. Even then, however, cases remained sparse, and onset in these individuals remained unreliable to the extent that statistical significance was not reached from examining Pfam domains on their own.

Supplementary Table 4

[a] Comparison of Patient Hazards Based on Diagnostic Variant Classification

Gene	VUS Predictions vs. P/LP Predictions (Mann Whitney U p-value)
BRCA1	5.11×10^{-17}
BRCA2	9.10×10^{-28}
LDLR	1.57×10^{-4}

[b] Average Partial Hazard Predictions by Gene and Variant Classification (95% CI)

Gene	Variant of Uncertain Significance (VUS)	Pathogenic / Likely Pathogenic (P/LP)
BRCA1	1.39 [1.3, 1.47]	7.06 [5.1, 9.01]
BRCA2	1.51 [1.45, 1.57]	6.51 [5.19, 7.83]
LDLR	2.18 [2.04, 2.33]	3.43 [2.3, 4.57]

[c] Phenotype Development Among High and Low-Risk Individuals With No Variant

Gene	Phenotype	Partial Hazard Cutoff	Development Among Individuals Below Cutoff	Development Among Individuals Above Cutoff	Phenotype Development χ^2 p-value
APOB	CAD	2.1	985 / 92891=0.011	2230 / 34237=0.065	p < 10 ^ -87
LDLR	CAD	2.8	1320 / 61841=0.021	1779 / 14272=0.12	p < 10 ^ -87
PCSK9	CAD	3.0	1423 / 101743=0.014	643 /19416=0.085	p < 10 ^ -87
BRCA1	BC	2.5	3022 / 42632=0.071	253 / 1116=0.23	2.5 * 10^-64
BRCA2	BC	2.3	2971 / 42557=0.070	371 / 1695=0.22	1.21 * 10^-87

Supplementary Table 4: [a] We see individuals with Pathogenic or Likely Pathogenic variants receiving higher predicted hazard scores than individuals with Variants of Uncertain Significance (VUS). While by and large these annotations are recapitulated through our predictions, these classifications alone are not sufficient at separating those with increased risk of the associated condition (see Figure 4). **[b]** Along with higher distributions of scores overall, Individuals with VUS received a lower predicted hazard score on average. **[c]** Condition development rates among those we define as high and low-risk within the UKB among those without variants.

Supplementary Table 5

Individual-level features among P/LP carriers in CAD-associated genes

Group	Proportion With Family History of CAD (+/- s.e.m.)	Proportion Male (+/- s.e.m.)	Mean PRS (95% CI)
High-Risk P/LP Carriers	0.62 [0.56, 0.67]	0.85 [0.81, 0.89]	0.40 [0.18, 0.62]
Low-Risk P/LP Carriers	0.52 [0.48, 0.56]	0.14 [0.11, 0.16]	0.01 [-0.16, 0.17]

Supplementary Table 5: Individual-level feature differences can largely explain differences in risk predictions among individuals with *APOB*, *LDLR, and PCSK9* variants. Among those with lab classified P/LP variants, we find significant differences in polygenic risk, sex makeup, and family history of CAD between those with predicted partial hazard scores below the high-risk threshold and those above it.

Supplementary Table 6

LDL levels among variant carriers in CAD-associated genes

Group	Average LDL Level (95% CI)
High-risk P/LP carriers	208.84 [198.47, 219.21]
Low-risk P/LP carriers	203.81 [196.04, 211.58]
High-risk VUS carriers	148.36 [146.47, 150.26]
Low-risk VUS carriers	140.51 [139.69, 141.34]
Non Carriers	143.81 [143.63, 143.99]

Supplementary Table 7

[a] Predicted Hazards in MyCode Participants With Non-Synonymous Variants Unobserved in the UK Biobank with Phenotype by Age 65

Gene	Phenotype	Individuals with Phenotype	Individuals without Phenotype	Average Score among Positive Phenotypes (95% CI)	Average Score among Negative Phenotypes (95% CI)	Mann-Whitney U p-value
APOB	CAD	25	137	2.26 [1.17, 3.35]	1.43 [1.17, 1.7]	0.11
LDLR	CAD	22	28	5.53 [3.27, 7.78]	2.08 [1.04, 3.13]	0.0010
PCSK9	CAD	2	16	3.76 [-33.6, 41.13]	2.17 [1.03, 3.3]	0.22
BRCA1	BC	1	14	7.15 [N/A, N/A]	0.81 [0.61, 1.02]	0.066
BRCA2	BC	4	52	1.53 [-0.44, 3.51]	1.24 [1.01, 1.47]	0.42

[b] Phenotype by Age 65 Among MyCode Participants With Non-Synonymous Variants Previously Unobserved in UK Biobank Participants

Gene	Phenotype	Partial Hazard Cutoff	Development Among Individuals Above Cutoff	Development Among Individuals Below Cutoff	Age 65 Risk Ratio (95% CI)	Phenotype Development χ^2 p-value
APOB	CAD	2.1	9 / 38	16 / 124	1.84 [1.1 , 2.57]	0.18
LDLR	CAD	2.8	12 / 17	10 / 33	2.33 [1.73 , 2.93]	0.016
PCSK9	CAD	3.0	1 / 5	1 / 13	2.6 [0.03, 5.17]	0.93
BRCA1	BC	2.5	1 / 1	0 / 14	N/A	0.072
BRCA2	BC	2.3	1 / 4	3 / 52	4.33 [2.31 , 6.36]	0.67

Supplementary Table 7: Testing model consistency when making predictions on a set of participants outside of the UKBk (see Figure 5). Here we restrict to individuals with non-synonymous variants that were not previously unobserved in the UKB. **[a]** Despite considerably lower statistical power than previous comparisons with no filter on observed variants, average predicted score tends to align with condition development, and statistical significance was still achieved (Mann-Whitney U p-value < 0.05) in some of the models' prediction distributions. **[b]** Validation of classification thresholds in partitioning high and low-risk individuals in five genes with their related phenotypes when restricting to variants not previously observed in the UKB participants. While limited in some cases by small sample sizes, development rates seem higher in those with scores above our thresholds, as expected, and significance is still reached in some of the genes' predictive models.

Supplementary Table 8

[a] Phenotype Development Rate Within the Geisinger Biobank

Phenotype	Development By Age 60	Development Within Lifetime
CAD	6.81%	17.24%
Breast Cancer	1.27%	2.50%

[b] Phenotype Development Rate Within the UK Biobank

Phenotype	Development By Age 60	Development Within Lifetime
CAD	3.81%	4.76%
Breast Cancer	4.74%	5.89%

Supplementary Table 8: Overall incidence of the tested conditions in the Geisinger MyCode biobank and in the UKB. Breast cancer development rates are limited to only female participants. Development rates are relative to the size of the overall biobank populations respectively.

Supplementary Figure 1



Supplementary Figure 1: Univariate regressions of individual-level or variant-level predictive features for incidence of CAD, by age. Cox proportional hazards model fit using UKB patients to make predictions of CAD risk for patients with variants in *LDLR***.** The model is fit using data for individual-level risk, including patient sex, family history of CAD, and polygenic risk score for CAD, as well as variant-level characteristics. All patient data are age-censored, using age at enrollment for prevalent CAD or time of incidence during the study period. Predictions can then be personalized using each individual's variant-level and individual-level characteristics and age.

Supplementary Figure 2

Risk Captured In Each Gene's Region as Defined by our Partition Method



Supplementary Figure 2: Each gene carries a differing level of risk from presence of a missense variant **(Supplementary Table 1).** We define regions of high and low risk as relative to each gene's overall missense risk. Using univariate regressions on regions we define high risk as being above 1.1 $\log_2$ Fold Change from missense risk, and low risk as being below 0.90 $\log_2$ Fold Change from missense risk. Red bars indicate above 1.1 LFC, blue bars indicate below 0.9 LFC.

Supplementary Figure 3

Breast Cancer Onset in Individual Pfam Domains and Their Underlying Region Defined by Our Partitions.



Supplementary Figure 3: *BRCA2* Pfam domains overlap with our partitioned regions 8-10. In addition to few carriers in these domains, there are no significant differences in breast cancer onset among those with variants in the underlying regions but outside of Pfam domains. Individuals included in cyan KM curves have variants outside of all Pfam domains, not solely that domain specified in the comparison.

Supplementary Figure 4

Clinical outcomes by risk classification among VUS carriers

[a]



[b]



[c]



Supplementary Figure 4: [a] We find large differences in clinical risk for coronary artery disease (CAD) and breast cancer. Among individuals with VUSs in these genes, we find large differences in clinical outcomes among those we classify as high risk (HR), and those we classify as low risk (LR) RR=3.71 [3.53, 3.90] for breast cancer, RR=4.71 [4.50, 4.92] for CAD **[b]** Results are still significant when restricting to only individuals with missense VUSs: RR=2.90 [2.60, 3.20] for breast cancer, RR=4.52 [4.31, 4.73] for CAD. **[c]** Results are still significant when restricting to only those with variants unreported in ClinVar: RR=2.71 [2.26, 3.16] for breast cancer, RR=3.75 [4.26, 3.25] for CAD.

Supplementary Figure 5

Carrier clinical outcomes by when restricting to VUS subsets

[a]



[b]



Supplementary Figure 5: [a] Risk thresholds separate individuals with high and low clinical risk in all five genes examined ($p < 10^{-6}$ in all cases) when limiting to only missense variants as VUSs. Additionally, we see no significant difference in risk when comparing individuals with VUS who fall below the threshold, and individuals with synonymous variants. Further, those individuals with lab-classified P/LP variants above the risk threshold did not develop the associated condition at higher rates than those with VUS in the same score range. **[b]** Many comparisons still reach significant thresholds when limiting to VUSs unreported in ClinVar despite much smaller sample sizes in some genes.

Supplementary Figure 6

Clinical outcomes among individuals in groups of low variant diversity or in low statistically powered groups

[a]



[b]



Supplementary Figure 6: [a] In *APOB,* we analyze only one P/LP missense variant (2-21006288-C-T p.Arg3527Gln), which was highly penetrant for coronary artery disease (CAD) risk. Unsurprisingly, carriers of this variant develop CAD at higher rates than high-risk VUS carriers. Of 116 carriers, we predict 51 to be at high risk and 65 to be low risk. In *PCSK9,* among the 15 P/LP carriers only one individual developed CAD. 14/15 of these individuals were predicted to be low-risk, including the one individual who developed CAD. **[b]** Despite this single *APOB* variant being highly linked to CAD, we still find those we predict as high-risk develop CAD at a higher rate (RR=3.79 [2.68, 4.90] logrank p=0.00035) than those we predict as low-risk. In *LDLR,* we see similar outcomes with those predicted to be high-risk developing CAD at higher rates than those we predict as low-risk (RR=3.27 [1.95, 4.60] logrank p=0.076). In *PCSK9*, only 15 individuals carry known pathogenic variants, which may limit our ability to distinguish between HR and LR carriers of pathogenic variants.

Regeneron Genetics Center and Geisinger DiscovEHR Collaboration Banner Author List and Contribution Statements
All authors/contributors are listed in alphabetical order.

Geisinger personnel
Lance J. Adams, Jackie Blank, Dale Bodian, Derek Boris, Adam Buchanan, David J. Carey, Ryan D. Colonie, F. Daniel Davis, Dustin N. Hartzel, Melissa Kelly, H. Lester Kirchner, Joseph B. Leader, J. Neil Manus, Christa L. Martin, Michelle Meyer, Tooraj Mirshahi, Matthew Oetjens, Christopher Still, Natasha Strande, Amy Sturm, Marc Williams

RGC Management and Leadership Team
Goncalo Abecasis, Aris Baras, Michael Cantor, Giovanni Coppola, Andrew Deubler, Aris Economides, Luca A. Lotta, John D. Overton, Jeffrey G. Reid, Alan Shuldiner, Katia Karalis and Katherine Siminovitch

Contribution: All authors contributed to securing funding, study design and oversight. All authors reviewed the final version of the manuscript.

Sequencing and Lab Operations
Christina Beechert, Caitlin Forsythe, Erin D. Fuller, Zhenhua Gu, Michael Lattari, Alexander Lopez, John D. Overton, Thomas D. Schleicher, Maria Sotiropoulos Padilla, Louis Widom, Sarah E. Wolf, Manasi Pradhan, Kia Manoochehri, Ricardo H. Ulloa.

Contribution: C.B., C.F., A.L., and J.D.O. performed and are responsible for sample genotyping. C.B, C.F., E.D.F., M.L., M.S.P., L.W., S.E.W., A.L., and J.D.O. performed and are responsible for exome sequencing. T.D.S., Z.G., A.L., and J.D.O. conceived and are responsible for laboratory automation. M.S.P., K.M., R.U., and J.D.O are responsible for sample tracking and the library information management system.

Genome Informatics
Xiaodong Bai, , Suganthi Balasubramanian, Boris Boutkov, Gisu Eom, Lukas Habegger, Alicia Hawes, Shareef Khalid, Olga Krasheninina, Rouel Lanche, Adam J. Mansfield, Evan K. Maxwell, Mona Nafde, Sean O'Keeffe, Max Orelus, Razvan Panea, Tommy Polanco, Ayesha Rasool, Jeffrey G. Reid, William Salerno, Jeffrey C. Staples,

Contribution: X.B., A.H., O.K., A.M., S.O., R.P., T.P., A.R., W.S. and J.G.R. performed and are responsible for the compute logistics, analysis and infrastructure needed to produce exome and genotype data. G.E., M.O., M.N. and J.G.R. provided compute infrastructure development and operational support. S.B., S.K., and J.G.R. provide variant and gene annotations and their functional interpretation of variants. E.M., J.S., R.L., B.B., A.B., L.H., J.G.R. conceived and are responsible for creating, developing, and deploying analysis platforms and computational methods for analyzing genomic data.

Pharmacogenomics Genetics:
Charles Paulding

Contribution: Contributed to the review process for the final version of the manuscript

Research Program Management
Marcus B. Jones, Jason Mighty, and Lyndon J. Mitnaul

Contribution: All authors contributed to the management and coordination of all research activities, planning and execution. All authors contributed to the review process for the final version of the manuscript.